Research Papers:

Transducin (β)-like 1 X-linked receptor 1 correlates with clinical prognosis and clinicopathological characteristics in human solid carcinomas

Fangteng Liu, Hui Gao, Yang Zhao and Zhengming Zhu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:61626-61636. https://doi.org/10.18632/oncotarget.18650

Metrics: PDF 1845 views  |   HTML 1831 views  |   ?  


Fangteng Liu1,*, Hui Gao2,*, Yang Zhao3,* and Zhengming Zhu1

1Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China

2The Children’s Hospital of Zhejiang University School of Medicine, Hangzhou 310052, Zhejiang Province, P. R. China

3Nanchang University School of Public Health, Nanchang 330031, Jiangxi Province, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Zhengming Zhu, email: [email protected]

Keywords: TBL1XR1, cancer, prognosis, clinicopathology, biomarker

Received: March 14, 2017     Accepted: May 15, 2017     Published: June 27, 2017


Transducin (β)-like 1 X-linked receptor 1(TBL1XR1) has been reported to be overexpressed in various human cancers, as well as contributing to carcinogenesis and progression. This synthetic analysis was performed to assess whether TBL1XR1 protein could act as a potential prognostic molecular marker for human cancers. Several online databases (PubMed, Web of Science, Embase together with Wanfang and China National Knowledge Internet database) were retrieved to identify TBL1XR1-related publications. A total of ten studies with 1837 cancer patients were included in this meta-analysis. Hazard ratios (HR) with 95% confidence intervals (CI) were applied to assess the association between TBL1XR1 expression and cancer prognosis. Odds ratios (OR) were calculated to determine the relationship between TBL1XR1 expression and clinicopathological characteristics. The overall results revealed that the overexpression of TBL1XR1 was correlated with poorer overall survival (OS) (HR: 1.77, 95% CI: 1.49–2.06, p < 0.001) and worse disease-free survival (DFS) (HR: 1.51, 95% CI: 1.19–1.84, p < 0.001) in human solid cancers. Statistical significance for OS was also found in subgroup analysis stratified by the cancer type, analysis method and follow-up time. Furthermore, elevated TBL1XR1 was associated with unfavorable clinicopathological characteristics including tumor size, depth of invasion, lymph node metastasis and TNM stage. Our meta-analysis suggested that TBL1XR1 might be served as a novel and promising biomarker to predict prognosis and clinicopathologic characteristic for cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18650